Drug Price Transparency in Medicaid Act of 2019

10/28/2022, 1:46 AM

Congressional Summary of HR 5281

Drug Price Transparency in Medicaid Act of 2019

This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions, dispensing fees, and survey participation to be made publicly available.

Current Status of Bill HR 5281

Bill HR 5281 is currently in the status of Bill Introduced since December 3, 2019. Bill HR 5281 was introduced during Congress 116 and was introduced to the House on December 3, 2019.  Bill HR 5281's most recent activity was Referred to the Subcommittee on Health. as of December 4, 2019

Bipartisan Support of Bill HR 5281

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
1
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 5281

Primary Policy Focus

Health

Potential Impact Areas

Business recordsCongressional oversightGovernment information and archivesHealth care costs and insuranceHome and outpatient careInflation and pricesMedicaidPrescription drugsPublic contracts and procurementRetail and wholesale tradesState and local government operationsUser charges and fees

Alternate Title(s) of Bill HR 5281

Drug Price Transparency in Medicaid Act of 2019To amend title XIX of the Social Security Act to improve transparency and prevent the use of abusive spread pricing and related practices in the Medicaid program.Drug Price Transparency in Medicaid Act of 2019
Start holding our government accountable!

Comments